Abstract
Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation of tumor cell proliferation and migration, tumor angiogenesis, or resistance to drugs, thus contributing to cancer progression and metastasis occurrence. Here, we focus on the clinical significance and potential mechanisms underlying the pathologic role of ACKR3 in breast, lung, and brain cancer and discuss its possible relevance as a prognostic factor and potential therapeutic target in these contexts.
| Original language | English |
|---|---|
| Pages (from-to) | 819-825 |
| Number of pages | 7 |
| Journal | Molecular pharmacology |
| Volume | 96 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Dec 2019 |
Funding
This work was supported by the European Union H2020-MSCA Program [Grant Agreement 64183], ONCORNET to P.M., M.J.S., and F.M.; Ministerio de Economía, Industria y Competitividad of Spain [Grant SAF2017-84125-R] to F.M.; CIBERCV-Instituto de Salud Carlos III, Spain [Grant CB16/11/00278] to F.M.; cofunded with European FEDER contribution, Comunidad de Madrid [B2017/BMD-3671-INFLAMUNE] to F.M.; Fundación Ramón Areces to F.M.; Portuguese Foundation for Science and Technology [Grant SFRH/BD/136574/ 2018] to M.N.; Netherlands Organization for Scientific Research NWO: Vici [Grant 016.140.657] to M.J.S.; and grants from CNRS, INSERM, Université de Montpellier and Fondation pour la Recherche Médicale (FRM) to P.M. 1A.F. and J.v.d.B. contributed equally to this work. https://doi.org/10.1124/mol.118.115279.
| Funders | Funder number |
|---|---|
| CIBERCV-Instituto de Salud Carlos III | CB16/11/00278 |
| European Union H2020-MSCA Program | 64183 |
| ONCORNET | |
| Fundación Ramón Areces | |
| Horizon 2020 Framework Programme | 641833 |
| Comunidad de Madrid | B2017/BMD-3671-INFLAMUNE |
| Institut national de la santé et de la recherche médicale | |
| Fundação para a Ciência e a Tecnologia | SFRH/BD/136574/ 2018 |
| Fondation pour la Recherche Médicale | |
| Federación Española de Enfermedades Raras | |
| Nederlandse Organisatie voor Wetenschappelijk Onderzoek | 016.140.657 |
| Centre National de la Recherche Scientifique | |
| Université de Montpellier | |
| Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España | SAF2017-84125-R |
